| Q41421852 | A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect |
| Q60175879 | Activating the Nucleic Acid-Sensing Machinery for Anticancer Immunity |
| Q58787920 | Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy |
| Q60956640 | Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines? |
| Q91322503 | An RNA toolbox for cancer immunotherapy |
| Q38666304 | An Update on the Use of Immunotherapy in the Treatment of Lymphoma |
| Q37130209 | CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy |
| Q89347786 | Dendritic cell-based immunotherapy |
| Q51148937 | Exogenous Stimulation of Type I Interferon Protects Mice with Chronic Granulomatous Disease from Aspergillosis through Early Recruitment of Host-Protective Neutrophils into the Lung. |
| Q64071651 | Harnessing Dendritic Cells for Poly (D,L-lactide--glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy |
| Q36350381 | Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. |
| Q60959909 | Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend |
| Q64071120 | Immunotherapeutic effects of intratumoral nanoplexed poly I:C |
| Q38727470 | In situ vaccination for the treatment of cancer. |
| Q38657642 | In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. |
| Q26991976 | In-situ tumor vaccination: Bringing the fight to the tumor |
| Q39043844 | Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally |
| Q38518518 | Intratumoral immunotherapy for melanoma |
| Q90066938 | Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies |
| Q36315857 | Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C |
| Q50676824 | Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. |
| Q60924965 | Modulation of double-stranded RNA pattern recognition receptor signaling in ovarian cancer cells promotes inflammatory queues |
| Q38877110 | Modulation of innate immunity in the tumor microenvironment |
| Q98177661 | Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model |
| Q64063100 | Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial |
| Q92943708 | Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor |
| Q64057061 | Strategies for developing and optimizing cancer vaccines |
| Q36413746 | TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression |
| Q47097756 | The current status of immunobased therapies for metastatic renal-cell carcinoma |
| Q57818348 | The double stranded RNA analog poly-IC elicits both robust IFN-λ production and oncolytic activity in human gastrointestinal cancer cells |
| Q61809073 | Therapeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation |
| Q57462243 | Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial |
| Q38867794 | Toward RNA nanoparticle vaccines: synergizing RNA and inorganic nanoparticles to achieve immunopotentiation |
| Q35799377 | Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma |
| Q99552005 | Trial watch: TLR3 agonists in cancer therapy |
| Q38259510 | Vaccine adjuvant uses of poly-IC and derivatives |
| Q26752522 | Vaccine adjuvants as potential cancer immunotherapeutics |
| Q26796314 | Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges |